Update on the therapy of highly aggressive non-Hodgkin's lymphoma.
This review focuses on the current understanding of the biology of highly aggressive non-Hodgkin's lymphomas, such as Burkitt's lymphoma, lymphoblastic lymphoma and adult T cell lymphoma/leukaemia. Specifically, this review will examine how our increased understanding of the pathophysiology of these diseases can be used to develop new therapies.
Jacobsen
Eric
E
Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA. Eric_Jacobsen@dfci.harvard.edu
LaCasce
Ann
A
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000188:drug therapy / Q000503:physiopathology; D002648:Child; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000503:physiopathology